Eyenovia Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Eyenovia şirketinin toplam hissedar öz sermayesi $3.7M ve toplam borcu $11.6M olup, bu da borç-öz sermaye oranını 311.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $22.8M ve $19.1M dir.

Anahtar bilgiler

311.1%

Borç/özkaynak oranı

US$11.57m

Borç

Faiz karşılama oranı	n/a
Nakit	US$7.19m
Eşitlik	US$3.72m
Toplam yükümlülükler	US$19.08m
Toplam varlıklar	US$22.80m

Son finansal sağlık güncellemeleri

Recent updates

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Jan 30

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Oct 14

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Jun 27

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Oct 25

Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential

Oct 05

Eyenovia names Michael Rowe as new CEO

Jul 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: EYEN 'nin kısa vadeli varlıkları ( $11.7M ) kısa vadeli yükümlülüklerini ( $15.8M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: EYEN şirketinin kısa vadeli varlıkları ( $11.7M ) uzun vadeli yükümlülüklerini ( $3.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: EYEN 'nin net borç/öz sermaye oranı ( 117.8% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: EYEN şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 311.1% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: EYEN son raporlanan serbest nakit akışına göre 3 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: EYEN serbest nakit akışı tahminlerine göre 3 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Eyenovia Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Eyenovia, Inc. Receives A Letter from the Staff of the Nasdaq Stock Market Regarding Bid Price Requirement

Eyenovia Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Recent updates

New minor risk - Profitability

New major risk - Market cap size

Eyenovia, Inc. Provides Update on Phase 3 CHAPERONE Study

Eyenovia, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Eyenovia, Inc. Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Eyenovia, Inc. Receives A Letter from the Staff of the Nasdaq Stock Market Regarding Bid Price Requirement

Eyenovia, Inc. Announces Chief Financial Officer Changes

Eyenovia, Inc. has completed a Follow-on Equity Offering in the amount of $5.14 million.

Eyenovia, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

Consensus revenue estimates decrease by 47%

Price target decreased by 11% to US$8.33

Eyenovia, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Eyenovia Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Consensus revenue estimates decrease by 32%, EPS upgraded

Eyenovia, Inc. to Report Q1, 2024 Results on May 15, 2024

Eyenovia, Inc., Annual General Meeting, Jun 12, 2024

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension

New major risk - Share price stability

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Eyenovia, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Price target decreased by 8.6% to US$10.67

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 33%

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 54%

New minor risk - Share price stability

High number of new directors

Eyenovia, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Eyenovia, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Insider recently bought US$234k worth of stock

Eyenovia, Inc., Annual General Meeting, Jun 27, 2023

Eyenovia, Inc. Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis

Eyenovia, Inc. to Report Q1, 2023 Results on May 11, 2023

Co-Founder recently sold US$300k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

No longer forecast to breakeven

No longer forecast to breakeven

Eyenovia, Inc. Showcases Microdose Array Print (MAP™) Technology At CES 2023 in Las Vegas

Eyenovia, Inc. Announces Positive Results from a Research Study

Forecast to breakeven in 2025

High number of new directors

Eyenovia Aims to Revolutionize Ophthalmology Devices with Microdose Array Print (Map) Technology

Eyenovia, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

Eyenovia, Inc. Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President, Effective January 1, 2023 and Julia Haller Steps Down from its Board of Directors

Price target decreased to US$14.33

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Eyenovia, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Eyenovia, Inc Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential

Eyenovia, Inc. Announces Retirement of Ken Lee as Lead Independent Director

Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First

First half 2022 earnings released

Eyenovia, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Eyenovia, Inc. Announces Board Changes

Eyenovia names Michael Rowe as new CEO